Inhibrx Net Income 2020-2022 | INBX
Inhibrx net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
| Inhibrx Annual Net Income (Millions of US $) |
|
|---|---|
| 2021 | $-82 |
| 2020 | $-76 |
| 2019 | $-51 |
| Inhibrx Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2022-03-31 | $-31 |
| 2021-12-31 | $-21 |
| 2021-09-30 | $-21 |
| 2021-06-30 | $-21 |
| 2021-03-31 | $-19 |
| 2020-12-31 | $-18 |
| 2020-09-30 | $-20 |
| 2020-06-30 | $-18 |
| 2020-03-31 | $-20 |
| 2019-12-31 | |
| 2019-09-30 | $-20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.458B | $0.007B |
| Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $168.111B | 10.23 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.121B | 30.63 |
| QIAGEN (QGEN) | Netherlands | $10.588B | 16.71 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.141B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.081B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.832B | 46.46 |
| Emergent Biosolutions (EBS) | United States | $1.646B | 7.05 |
| Myovant Sciences (MYOV) | United Kingdom | $1.264B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.364B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.116B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.111B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.102B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.099B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
